Screening for lung cancer has been proposed for decades. It is fundamentally based on the principle that tumors will be detected at a smaller size and earlier stage, when treatment is more effective, resulting in a reduction in lung cancer mortality.
1,2 An ideal screening program targets individuals at the highest risk of lung cancer, uses a cost-effective test to detect tumors at an early stage, and efficiently excludes patients with clinically insignificant abnormalities.